Early Access

10-QPeriod: Q1 FY2021

HCA Healthcare, Inc. Quarterly Report for Q1 Ended Mar 31, 2021

Filed April 30, 2021For Securities:HCA

Summary

HCA Healthcare, Inc. reported strong financial performance for the first quarter of 2021, with total revenues reaching $13.977 billion, an increase of 8.7% compared to the prior year. This revenue growth was driven by a significant 16.1% increase in revenue per equivalent admission, despite a 6.4% decline in equivalent admissions. This suggests a shift towards higher-acuity patients and favorable changes in payer mix, which offset lower patient volumes. Net income attributable to HCA Healthcare, Inc. saw a substantial jump to $1.423 billion, or $4.14 per diluted share, a significant increase from $581 million, or $1.69 per diluted share, in the first quarter of 2020. This robust profitability, coupled with strong operating cash flow of $1.988 billion, indicates effective cost management and operational efficiency in a recovering healthcare environment. The company also demonstrated a commitment to shareholder returns through substantial share repurchases and consistent dividend payments.

Financial Statements
Beta
Revenue$13.98B
Operating Expenses$12.00B
Interest Expense$384.00M
Net Income$1.42B
EPS (Basic)$4.21
EPS (Diluted)$4.14
Shares Outstanding (Basic)338.12M
Shares Outstanding (Diluted)343.32M

Key Highlights

  • 1Revenues increased by 8.7% to $13.977 billion in Q1 2021, driven by a 16.1% rise in revenue per equivalent admission, indicating improved pricing power and/or a shift to higher-margin services.
  • 2Net income attributable to HCA Healthcare, Inc. more than doubled to $1.423 billion ($4.14 EPS) from $581 million ($1.69 EPS) in Q1 2020, showcasing significant profit growth.
  • 3Operating cash flow improved by 44.6% to $1.988 billion in Q1 2021, up from $1.375 billion in Q1 2020, highlighting strong cash generation capabilities.
  • 4Patient volumes (equivalent admissions) decreased by 6.4% year-over-year, suggesting a continued impact from the COVID-19 pandemic on elective procedures and non-urgent care, though recovery is indicated by revenue growth.
  • 5Salaries and benefits as a percentage of revenue decreased to 45.1% from 47.6%, indicating improved labor cost management relative to revenue.
  • 6The company actively returned capital to shareholders, repurchasing approximately $1.527 billion in common stock during Q1 2021 and authorizing an additional $6 billion for future repurchases.
  • 7Despite a decline in uninsured admissions (down 15.8%), overall uncompensated care costs decreased to $778 million from $937 million, suggesting better management of patient financial responsibility and potentially favorable impacts from COVID-19 related reimbursements.

Frequently Asked Questions